# LLM Judge Evaluation: tier3_003

## Overall: FAIL

### Scores:
- **Completion**: 1/2
- **Correctness**: 1/2
- **Tool Use**: 1/2
- **Total**: 3/6

### Reasoning:
Completion:
- The task required: (a) generate conformers, (b) dock the top 5 conformers to HMG‑CoA reductase (PDB: 1HWK), (c) calculate binding energies, and (d) compare to the crystal conformation.
- Conformers: Completed (50 generated; workflow finished).
- Docking: Only one docking workflow was run (for a single conformer), not the top 5; no per‑conformer comparison.
- Binding energies: Reported docking scores for poses from that single run; no energies per top 5 conformers; no MM/GBSA or equivalent.
- Crystal comparison: No explicit extraction of the co‑crystallized atorvastatin from 1HWK, no redocking or RMSD-to-crystal calculation; comparison was narrative only.
→ Result: Partially completed.

Correctness:
- Identity of 1HWK as HMGR with atorvastatin is correct. ([rcsb.org](https://www.rcsb.org/structure/1HWK?utm_source=openai))
- Reported molecular properties: MW (~558.6 g/mol), logP (~6.3), HBD=4, HBA=5, rotatable bonds=12 align with DrugBank/Chemaxon data; however TPSA was reported as ~180 Å², which conflicts with widely cited values near 112 Å². ([go.drugbank.com](https://go.drugbank.com/drugs/DB01076?utm_source=openai))
- Claimed potency “IC50 ~ 8 nM” is not universally supported; literature shows assay-dependent values (e.g., 40–100 nM in human liver microsomes), although some curated sources list single‑digit nM potencies (likely different assay/species/conditions). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10965989/?utm_source=openai))
- Docking “binding energies” were reported as docking scores for a single conformer; no validation against the co‑crystal (e.g., redocking RMSD) was shown.

Tool use:
- Tools were used in a logical sequence for conformer generation and single docking. However:
  - “Top 5 conformers” were not actually docked; only one docking workflow was submitted.
  - Docking used a SMILES (letting the docker generate poses) rather than the saved 3D geometries for each selected conformer; this undermines the “per‑conformer” requirement.
  - Pocket box appears arbitrary and was not derived from the co‑crystal ligand coordinates; no mention of cofactors/retained waters.
  - No structural alignment/RMSD step to compare docked poses to the crystal ligand.

Overall: Partial completion with several methodological gaps and some property inconsistencies (notably TPSA).

### Feedback:
- You did generate conformers and complete one docking run, but the task explicitly required docking the top 5 conformers. Please run five separate dockings using the saved 3D geometries of the top 5 conformers (not just SMILES) so conformer‑specific results are auditable.
- Define the binding pocket from the co‑crystallized atorvastatin coordinates in 1HWK (e.g., ligand‑centric box + padding) and retain catalytically relevant cofactors/waters if present. Then remove the ligand for docking. ([rcsb.org](https://www.rcsb.org/structure/1HWK?utm_source=openai))
- Report per‑conformer results: docking score, strain energy (conformational penalty), and, if possible, post‑docking MM/GBSA estimates for binding energy with consistent receptor preparation.
- Perform a redocking control: extract atorvastatin from 1HWK, dock it back, and report heavy‑atom RMSD to the crystal pose (<2.0 Å is a common success criterion).
- Fix descriptor inconsistencies: your TPSA (180 Å²) disagrees with standard references (~112 Å²). Recompute TPSA for the correct neutral free‑acid tautomer and state the method/tool used. ([go.drugbank.com](https://go.drugbank.com/drugs/DB01076?utm_source=openai))
- When citing potency, acknowledge assay context (species, enzyme source, conditions). Present a range with sources rather than a single value to avoid over‑precision. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10965989/?utm_source=openai))
- Literature validation: - Target/structure check:
  - 1HWK is “Complex of the catalytic portion of human HMG‑CoA reductase with atorvastatin.” Verified via RCSB/NCBI/PDBj. ([rcsb.org](https://www.rcsb.org/structure/1HWK?utm_source=openai))

- Property validation (required numerical audit):
  1) LogP
     - Agent’s value: 6.314
     - Literature value: 6.36 (DrugBank experimental) ([go.drugbank.com](https://go.drugbank.com/drugs/DB01076?utm_source=openai))
     - Absolute error: 0.046
     - Percent error: 0.72%
     - Score justification: Within ±0.3 units → meets 2/2 criterion for this metric.

  2) Molecular weight (free acid)
     - Agent’s value: 558.253 g/mol
     - Literature value: 558.65 g/mol (DrugBank/other references) ([go.drugbank.com](https://go.drugbank.com/drugs/DB01076?utm_source=openai))
     - Absolute error: 0.397 g/mol
     - Percent error: 0.071%
     - Comment: Essentially matching.

  3) TPSA
     - Agent’s value: 180.127 Å²
     - Literature value: 111.79 Å² (DrugBank/Chemaxon) ([go.drugbank.com](https://go.drugbank.com/drugs/DB01076?utm_source=openai))
     - Absolute error: 68.34 Å²
     - Percent error: ~61%
     - Comment: Large discrepancy; suggests an incorrect descriptor report or different protonation/tautomer; typical references for atorvastatin list TPSA ≈ 112 Å².

- Potency (context for binding energy discussion; assay dependent):
  - Agent’s claim: “IC50 ~ 8 nM.”
  - Literature examples:
    - Human liver microsomes: atorvastatin IC50 between 40–100 nM. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10965989/?utm_source=openai))
    - Curated portal cites 8 nM IC50 (and 6.2 nM Ki, rat enzyme), indicating assay/species variability. ([chemicalprobes.org](https://www.chemicalprobes.org/atorvastatin?utm_source=openai))
  - Takeaway: The single‑digit nM claim is not universally representative; values vary substantially with system and conditions.

- Crystal comparison expectation:
  - Proper validation would include extracting the co‑crystal ligand from 1HWK and computing RMSD between redocked pose(s) and the crystallographic conformation. No such RMSD was reported.

### Web Search Citations:
1. [RCSB PDB - 1HWK: COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN](https://www.rcsb.org/structure/1HWK?utm_source=openai)
2. [Atorvastatin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB01076?utm_source=openai)
3. [HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins](https://pubmed.ncbi.nlm.nih.gov/10965989/?utm_source=openai)
4. [RCSB PDB - 1HWK: COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN](https://www.rcsb.org/structure/1HWK?utm_source=openai)
5. [Atorvastatin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB01076?utm_source=openai)
6. [Atorvastatin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB01076?utm_source=openai)
7. [Atorvastatin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB01076?utm_source=openai)
8. [HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins](https://pubmed.ncbi.nlm.nih.gov/10965989/?utm_source=openai)
9. [Probe Atorvastatin | Chemical Probes Portal](https://www.chemicalprobes.org/atorvastatin?utm_source=openai)
10. [RCSB PDB - 1HWK: COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN](https://www.rcsb.org/structure/1HWK?utm_source=openai)
11. [Atorvastatin: Uses, Interactions, Mechanism of Action | DrugBank Online](https://go.drugbank.com/drugs/DB01076?utm_source=openai)
12. [HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins](https://pubmed.ncbi.nlm.nih.gov/10965989/?utm_source=openai)

### Execution:
- **Tools**: sanitize_protein, retrieve_calculation_molecules, molecule_lookup, submit_docking_workflow, submit_descriptors_workflow, create_protein_from_pdb_id, submit_conformer_search_workflow, workflow_get_status, retrieve_workflow
- **Time**: 29.8 min

---
*Evaluated with openai/gpt-5*
